



CLAIMS

1. A compound of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt thereof, wherein

A is ,  or ;

Ring B is a 4- to 10-membered cycloalkyl; a 4- to 10-membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; a 4- to 10-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; or a 4- to 10-membered cycloalkenyl;

R^7 is selected from -H, -F, $-CH_3$ and $-OCH_3$;






each R^8 is independently selected from C_{1-4} alkyl substituted with 0-3 -F substituents; C_{1-4} alkoxy; -OH; -F; and $-COO(C_{1-4}$ alkyl);

p is 0, 1 or 2;

Ring C is a 6- to 10-membered aryl; a 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; a 4- to 10-membered cycloalkenyl; or a 4- to 10-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen;


each R^9 is independently selected from C_{1-4} alkyl, C_{1-4} alkoxy, -halo and -OH;

q is 0, 1 or 2;

R^1 is selected from -COOH, -$CONH_2$, -CONHMe, -$CONMe_2$, -$C(CH_2OH)_2NH_2$, -$C(NH)NH_2$, -SO_2NH_2, -$NHSO_2Me$, , , ,  and ;

X is selected from a bond, -CH_2-, -O-, -S-, -CH_2O- and -OCH_2-;

Y is selected from C_{2-6} alkylene substituted with 0-2 R^{14} substituents; C_{3-8} cycloalkylene substituted with 0-2 R^{14} substituents; C_{5-8} cycloalkenylene substituted with 0-2 R^{14} substituents; 5- to 8-membered heterocycloalkylene having 1-3 heteroatoms independently selected from oxygen and sulfur and substituted with 0-2 R^{14} substituents; phenylene substituted with 0-2 R^{14} substituents; 5- or 6-membered heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and substituted with 0-2 R^{14} substituents; and

;

R^{14} is selected from C_{1-3} alkyl substituted with 0-3 substituents selected from -OH, -OMe, -F and -CN; C_{1-3} alkoxy substituted with 0-3 -F substituents; cyclopropyl substituted with 0-3 substituents selected from -OH, -OMe, -F and -CN; -F; -OH; =O; -CN; -NH_2; -NHMe; and -NMe_2;

Z is selected from a bond; C_{1-3} alkylene substituted with 0-2 substituents selected from -Me, -NH_2, -NHMe and -NMe_2; C_{2-4} heteroalkylene having one heteroatom selected from nitrogen and oxygen and substituted with 0-2 substituents selected from -Me, -NH_2, -NHMe and -NMe_2; C_{3-4} cycloalkylene; and -CH=CH-;


R^5 is selected from -H, -Me and -F;


R^6 is -$(CR^{10}R^{11})_nR^{12}$;

n is 0, 1 or 2;

R^{10} and R^{11} are each independently selected from -H, -Me and -F, or R^{10} and R^{11} together with the carbon to which they are attached form cyclopropyl;

R^{12} is selected from C_{3-8} alkyl substituted with 0-5 substituents selected from -OH, -F, -CN, and C_{1-4} alkoxy; C_{3-10} cycloalkyl substituted with 0-4 R^{13} substituents; 5- to 10-membered heterocycloalkyl having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-4 R^{13} substituents; phenyl substituted with 0-3 substituents selected from -halo, C_{1-4} alkyl substituted with 0-3 -F substituents, C_{3-5} cycloalkyl, -CN, $-SF_5$, -OMe, $-OCH_2F$, $-OCHF_2$, $-OCF_3$ and $-SO_2CF_3$; 6-membered heteroaryl having 1-2 nitrogen heteroatoms and substituted with 1-3 substituents selected from -halo, $-SF_5$, $-CF_3$, $-OCF_3$ and $-SO_2CF_3$;



; and


;

each R^{13} is independently selected from -OH; -F; -CN; C_{1-4} alkoxy substituted with 0-3 substituents selected from -F, -OH, -OMe and -OEt; and C_{1-4} alkyl substituted with 0-3 substituents selected from -F, -OH, -OMe and -OEt;

U, V and W are each independently selected from C and N; provided that when U is N, R^2 is absent; when V is N, R^3 is absent; and when W is N, R^4 is absent;

and wherein

(i) R^2, R^3 and R^4 are each independently selected from -H, -halo, -CN, C_{1-4} alkyl substituted with 0-3 substituents selected from -F and -OMe, C_{1-4} alkoxy substituted with 0-3 substituents selected from -F and -OMe, C_{3-4} cycloalkyl substituted with 0-3 substituents selected from -F and -OMe, and C_{3-4} cycloalkoxy substituted with 0-3 substituents selected from -F and -Me; or

(ii) U and V are each C;

R^2 and R^3, together with the atoms to which they are attached, form a 5- or 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and substituted with 0-3 -Me substituents; and

R^4 is selected from -H, -halo, -CN, C_{1-4} alkyl substituted with 0-3 substituents selected from -F and -OMe, C_{1-4} alkoxy substituted with 0-3 substituents selected from -F and -OMe, C_{3-4} cycloalkyl substituted with 0-3 substituents selected from -F and -OMe, and C_{3-4} cycloalkoxy substituted with 0-3 substituents selected from -F and -Me; or

(iii) V and W are each C;

R^3 and R^4, together with the atoms to which they are attached, form a 5- or 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and substituted with 0-3 -Me substituents; and

R^2 is selected from -H, -halo, -CN, C_{1-4} alkyl substituted with 0-3 substituents selected from -F and -OMe, C_{1-4} alkoxy substituted with 0-3 substituents selected from -F and -OMe, C_{3-4} cycloalkyl substituted with 0-3 substituents selected from -F and -OMe, and C_{3-4} cycloalkoxy substituted with 0-3 substituents selected from -F and -Me;

wherein

cycloalkyl is a monocyclic, bicyclic, polycyclic, fused, bridged, or spirocyclic saturated aliphatic hydrocarbon group having the specified number of carbon atoms;

cycloalkoxy is a cycloalkyl group attached through an oxygen linking atom;

cycloalkenyl is a monocyclic, bicyclic, polycyclic, fused, bridged, or spirocyclic unsaturated aliphatic hydrocarbon group having the specified number of carbon atoms;

heterocycloalkyl is a monocyclic, bicyclic, polycyclic, fused, bridged, or spirocyclic saturated group containing carbon atoms and the specified number of heteroatoms in the ring structure, and having the specified total number of atoms in the ring structure;

heterocycloalkenyl is a monocyclic, bicyclic, polycyclic, fused, bridged, or spirocyclic unsaturated group containing carbon atoms and the specified number of heteroatoms in the ring structure, and having the specified total number of carbon atoms and heteroatoms in the ring structure;

heteroalkyl is an alkyl group in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur, and the specified number of members in the heteroalkyl group refers to the total number of carbon atoms and heteroatoms in the chain.

2. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Ring B is a monocyclic 5- to 7-membered cycloalkyl optionally bridged with C_{1-3} alkylene; or a monocyclic 5- to 7-membered cycloalkenyl optionally bridged with C_{1-3} alkylene.


3. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein Ring B is cyclohexyl 1,4-bridged with C_{1-2} alkylene, or cyclohexenyl 1,4-bridged with C_{1-2} alkylene, such as bicyclo[2.2.1]heptanyl.

4. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 3, wherein p is 0 and R^7 is -H.




5. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 4, wherein Ring C is phenyl; a monocyclic 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; a monocyclic 4- to 7-membered cycloalkenyl optionally bridged with C_{1-3} alkylene; or a monocyclic 4- to 7-




membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen and optionally bridged with C_{1-3} alkylene.



6. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 5,

wherein A is ,


such as A is selected from:


, , ,


, , ,


 and ,

such as A is selected from:




,


,


and


.

7. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 6,


wherein A is 

.


8. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 7, wherein R^1 is -COOH.


9. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 8, wherein X is -O-.

10. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 9, wherein Y is selected from C_{2-4} alkylene substituted with 0-2 R^{14} substituents; C_{3-8} cycloalkylene substituted with 0-2 R^{14} substituents; and 5- to 8-membered heterocycloalkylene having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-2 R^{14} substituents, such as Y is



, and r is 1, 2 or 3.



11. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 10, wherein Y is 

, such as Y is 

.

12. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 11, wherein R^{14} is selected from -H, -Me, -Et, -F, -OH, =O, -OMe, -OEt, $-CF_3$, $-CH_2OH$, $-CH_2OMe$, -CN, $-CH_2CN$, $-NH_2$, -NHMe and $-NMe_2$.


13. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 12, wherein R^{14} is -Me.


14. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 13, wherein Z is selected from a bond, $-CH_2-$, $-CH_2CH_2-$, $-OCH_2-$, $-CH_2O-$, $-C(CH_3)_2O-$, $-CH_2CH_2O-$, $-CH_2CH_2CH_2O-$, $-CH_2NH-$, $-CH(NH_2)-$, $-CH(NMe_2)-$, $-CH_2CH(NMe_2)-$, $-CH(NMe_2)CH_2-$, $-CH_2CH(NH_2)-$, $-CH(NH_2)CH_2-$, -CH=CH-, 
, and 
, such as Z is a bond.


15. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 14, wherein R^5 is -H.

16. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 15, wherein n is 0 or 1, such as n is 1.

17. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 16, wherein R^{10} and R^{11} are each -H.


18. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 17, wherein R^{12} is selected from 


, 

, and 


,

such as R^{12} is selected from



and



,


such as R^{12} is



.

19. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 17, wherein each R^{13} is independently selected from -F; -CN; C_{1-2} alkoxy substituted with 0-1 substituents selected from -F, -OMe and -Oet; and C_{1-2} alkyl substituted with 0-1 substituents selected from -F, -Ome and -Oet, such as each R^{13} is -Me.

20. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 19, wherein R^6 is selected from:





,


and


,


such as R^6 is selected from:



and


,

such as R^6 is:



.


21. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 20, wherein U, V and W are each C.

22. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 21, wherein R^2 is selected from -H, -halo, -CN, C_{1-2} alkyl substituted with 0-3 -F substituents, C_{1-2} alkyl substituted with 0-1 -OMe substituents, and cyclopropyl, such as R^2 is -CN or -F; R^3 is selected from -H, -halo, -CN, C_{1-2} alkyl substituted with 0-3 -F

substituents, C_{1-2} alkyl substituted with 0-1 -OMe substituents, and cyclopropyl, such as R^3 is -H; and R^4 is selected from -F and C_{1-4} alkoxy substituted with 0-3 substituents selected from -F and -OMe, such as R^4 is -OMe.


23. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 22, wherein R^2 is -F; R^3 is -H; R^4 is -OMe; and R^5 is -H.


24. The compound or pharmaceutically acceptable salt thereof of claim 1, which is a compound of Formula (IIIa):




(Formula IIIa),

or a pharmaceutically acceptable salt thereof.


25. The compound or pharmaceutically acceptable salt thereof of claim 24, wherein R^2 is -F or -CN; and R^6 is selected from 

, 

and 


.

26. The compound or pharmaceutically acceptable salt thereof of claim 1, which is the compound (1*S*,4*s*)-4-(2-Fluoro-4-methoxy-5-(((1S,2R,3S,4R)-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid:




or a pharmaceutically acceptable salt thereof.

27. The compound of claim 1, which is (1*S*,4*s*)-4-(2-Fluoro-4-methoxy-5-(((1S,2R,3S,4R)-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid:



.

28. The pharmaceutically acceptable salt according to claim 1, which is a pharmaceutically acceptable salt of (1*S*,4*s*)-4-(2-Fluoro-4-methoxy-5-(((1S,2R,3S,4R)-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid:



29. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 28 and a pharmaceutically acceptable excipient.

30. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 28 for use in therapy.

31. Use of the compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 28 in the manufacture of a medicament for the treatment of a subject with a disease or condition selected from the group consisting of heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury.